Patients with squamous cell carcinoma of the oral cavity are afflicted with a malignancy that frequently presents with advanced disease and whose management often has profound effects upon these individual's speech, swallowing, cosmetic appearance, as well as survival. Unfortunately, despite advances in contemporary surgery and radiation therapy over the past thirty years, survival among these patients has remained essentially unaltered. Additionally, chemotherapy has shown little promise in the management of these cancers. Therefore, developing novel mechanisms of cessating the premalignant processes which lead to these malignancies may provide the most significant advancements in this field of medicine. Gene therapy for premalignancy and carcinoma in-situ of the oral cavity may be very achievable. Topical transduction of epithelium which has undergone transformation in the premalignant process is likely to be efficacious. Initial investigations of wild-type p53 adenovirus has shown promise as a molecular intervention due to its function as a tumor suppressor gene and proposed role in apoptosis. However, significant advances are required in understanding the optimization of transduction efficiency in molecular therapy as well as increasing our understanding of the interaction of molecular intervention strategies in order to produce the desired affect of tumor cell demise and sparing of non-malignant cells. We have elected to employ the adenovirus vector as a mechanism for molecular intervention due to its characteristic transient expression, efficiency of expression, and ability to expand to high titers. Additionally, lack of permanent integration is favorable from a biosafety standpoint as compared to retrovirus vectors. This proposal therefore submits to further develop our understanding of apoptosis inducing gene therapy for premalignant and microinvasive squamous cell carcinoma of the oral cavity through the following specific aims: 1. To determine the maximal transfection efficiency of adenovirus vectors in the transient expression of marker genes in organotypic and tissue slice models of premalignancies of the oral cavity. 2. To determine the effectiveness of transient expression of wild-type p53, p16, p21 (CIP/WAF1), and pRB105 independently and in combination in the induction of apoptosis in oral squamous carcinoma cell lines and the models of premalignancy. 3. To determine whether regulation of transcription factors, including p21 (CIP/WAF1), E2F-1, and DP-1, which are downstream of p53, can further potentiate the induction of apoptosis in oral squamous carcinoma cells and the models of premalignancy. 4. To determine the effect of the optimized gene therapy strategies for induction of apoptosis, in premalignant oral cavity carcinomas, upon normal oral epithelium and stromal cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Specialized Center (P50)
Project #
3P50DE011906-05S1
Application #
6479437
Study Section
Project Start
2000-08-01
Project End
2002-07-31
Budget Start
Budget End
Support Year
5
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Wang, Heng; Hicks, John; Khanbolooki, Parham et al. (2003) Transgenic mice demonstrate novel promoter regions for tissue-specific expression of the urokinase receptor gene. Am J Pathol 163:453-64
Gonzalez, Hernan E; Gujrati, Manu; Frederick, Mitchell et al. (2003) Identification of 9 genes differentially expressed in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 129:754-9
Jayakumar, Arumugam; Kang, Ya'an; Frederick, Mitchell J et al. (2003) Inhibition of the cysteine proteinases cathepsins K and L by the serpin headpin (SERPINB13): a kinetic analysis. Arch Biochem Biophys 409:367-74
Chun, Kyung-Hee; Benbrook, Doris M; Berlin, K Darrell et al. (2003) The synthetic heteroarotinoid SHetA2 induces apoptosis in squamous carcinoma cells through a receptor-independent and mitochondria-dependent pathway. Cancer Res 63:3826-32
Higuchi, Eisaku; Chandraratna, Roshantha A S; Hong, Waun K et al. (2003) Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype. Oncogene 22:4627-35
Liu, Yanna; Li, Jun Z; Yuan, Xiao H et al. (2002) An AP-1 binding site mutation in HPV-16 LCR enhances E6/E7 promoter activity in human oral epithelial cells. Virus Genes 24:29-37
Yan, Chunhong; Wang, Heng; Boyd, Douglas D (2002) ATF3 represses 72-kDa type IV collagenase (MMP-2) expression by antagonizing p53-dependent trans-activation of the collagenase promoter. J Biol Chem 277:10804-12
El-Naggar, Adel K; Kim, Hyung W; Clayman, Gary L et al. (2002) Differential expression profiling of head and neck squamous carcinoma: significance in their phenotypic and biological classification. Oncogene 21:8206-19
Shin, M; Yan, C; Boyd, D (2002) An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim Biophys Acta 1589:311-6
Hayashi, K; Yokozaki, H; Naka, K et al. (2001) Overexpression of retinoic acid receptor beta induces growth arrest and apoptosis in oral cancer cell lines. Jpn J Cancer Res 92:42-50

Showing the most recent 10 out of 57 publications